{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:36:46Z","timestamp":1793860606861,"version":"4.6.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>RelabotulinumtoxinA (relaBoNT-A; Relfydess, Galderma, Uppsala, Sweden) is a novel, ready-to-use liquid form of botulinum toxin A, created using PEARL technology to produce a highly effective, complex-free formulation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study reports the patient-assessed effectiveness and satisfaction outcomes from the relaBoNT-A Phase 3 READY-1 study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adults with moderate-to-severe glabellar lines were randomized 3:1 to receive relaBoNT-A (50 U) or placebo in a 6-month, double-blind, multicenter study. Patient-reported endpoints at maximum frown included \u22651 grade improvement on the glabellar line subject live assessment (GL-SLA) scale from baseline and Global Aesthetic Improvement Scale (GAIS) score. Satisfaction and well-being investigations used the Facial Lines Treatment Satisfaction Questionnaire (FLTSQ), Natural Expressions Questionnaire, and FACE-Q Psychological Function Questionnaire.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 233 adults received relaBoNT-A and 74 received placebo. RelaBoNT-A responder rates for \u22651-grade GL-SLA improvement from baseline at Day 7 and Months 1, 3, and 6 were 97.2%, 97.7%, 90.0%, and 71.0%, respectively, vs 18.9%, 26.8%, 27.5%, and 22.4% with placebo (P &amp;lt; .001). GAIS responder rates were 74.3% to 98.1% (relaBoNT-A) and 9.0% to 16.2% (placebo). Posttreatment FLTSQ Rasch-transformed scores were higher with relaBoNT-A (\u226562.5) than placebo (\u226449.8) for the Appearance Module and Treatment Satisfaction Module (relaBoNT-A: \u226583.0; placebo: \u226436.8). RelaBoNT-A-treated patients reported looking natural (\u226583.3%) and feeling confident when making facial expressions (\u226575.7%). Mean change in FACE-Q well-being score was higher with relaBoNT-A (11.0-13.7) vs placebo (0.6-4.5).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Adults with moderate-to-severe glabellar lines receiving a single relaBoNT-A treatment reported significant improvements in glabellar line severity throughout the 6-month study period. RelaBoNT-A provided natural looking results, high satisfaction, and psychological well-being improvements.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Level of Evidence: 1 (Therapeutic)<\/jats:title>\n                  <jats:p\/>\n               <\/jats:sec>","DOI":"10.1093\/asj\/sjaf063","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T05:37:19Z","timestamp":1744868239000},"page":"828-835","source":"Crossref","is-referenced-by-count":11,"title":["Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use Liquid Formulation: Data From the Phase 3 READY-1 Trial"],"prefix":"10.1093","volume":"45","author":[{"given":"Michael H","family":"Gold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Donofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Shridharani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Biesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalyn","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristel","family":"Polder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9913-7709","authenticated-orcid":false,"given":"Nowell","family":"Solish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Schwarcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Karin","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Ax\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"2025071503264257900_sjaf063-B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/asj\/sjae188","article-title":"Aesthetic Plastic Surgery National Databank Statistics 2023","volume":"44","author":"The Aesthetic Society","year":"2024","journal-title":"Aesthet Surg J"},{"key":"2025071503264257900_sjaf063-B2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/cia.s9338","article-title":"Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction","volume":"5","author":"De Boulle","year":"2010","journal-title":"Clin Interv Aging"},{"key":"2025071503264257900_sjaf063-B3","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.1177\/1090820X12474632","article-title":"A review of abobotulinumtoxinA (Dysport)","volume":"33","author":"Lorenc","year":"2013","journal-title":"Aesthet Surg J"},{"key":"2025071503264257900_sjaf063-B4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/DSS.0000000000002013","article-title":"Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines","volume":"46","author":"Monheit","year":"2020","journal-title":"Dermatol Surg"},{"key":"2025071503264257900_sjaf063-B5","doi-asserted-by":"publisher","first-page":"988","DOI":"10.36849\/jdd.6130","article-title":"AbobotulinumtoxinA treatment of glabellar lines using a new reconstitution and injection volume: randomized, placebo-controlled data","volume":"20","author":"Schlessinger","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"2025071503264257900_sjaf063-B6","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1097\/DSS.0000000000001679","article-title":"Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment of upper facial lines","volume":"44","author":"Hexsel","year":"2018","journal-title":"Dermatol Surg"},{"key":"2025071503264257900_sjaf063-B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7181\/acfs.2021.00003","article-title":"Scientific review of the aesthetic uses of botulinum toxin type A","volume":"22","author":"Park","year":"2021","journal-title":"Arch Craniofac Surg"},{"key":"2025071503264257900_sjaf063-B8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/asj\/sjx179","article-title":"Impact of comprehensive, minimally invasive, multimodal aesthetic treatment on satisfaction with facial appearance: the HARMONY study","volume":"38","author":"Weinkle","year":"2018","journal-title":"Aesthet Surg J"},{"key":"2025071503264257900_sjaf063-B9","author":"Liljegren Sundberg"},{"key":"2025071503264257900_sjaf063-B10","author":"Do"},{"key":"2025071503264257900_sjaf063-B11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/CCID.S156851","article-title":"Botulinum neurotoxin formulations: overcoming the confusion","volume":"11","author":"Samizadeh","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2025071503264257900_sjaf063-B12","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/asj\/sjae131","article-title":"Efficacy and safety of relabotulinumtoxinA, a new ready-to-use liquid formulation botulinum toxin: results from the READY-1 double-blind, randomized, placebo-controlled phase 3 trial in glabellar lines","volume":"44","author":"Shridharani","year":"2024","journal-title":"Aesthet Surg J."},{"key":"2025071503264257900_sjaf063-B13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2147\/CCID.S446891","article-title":"The patient journey in facial aesthetics: findings from a European consensus meeting on improving the quality of life for patients receiving botulinum toxin injections","volume":"17","author":"Philipp-Dormston","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2025071503264257900_sjaf063-B14","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1016\/j.bjps.2022.08.063","article-title":"Impact of botulinum toxin for facial aesthetics on psychological well-being and quality of life: evidence-based review","volume":"75","author":"Pereira","year":"2022","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"2025071503264257900_sjaf063-B15","first-page":"E69","article-title":"Patient satisfaction with abobotulinumtoxinA for aesthetic use in the upper face: a systematic literature review and post-hoc analysis of the APPEAL study","volume":"14","author":"Smit","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"key":"2025071503264257900_sjaf063-B16","doi-asserted-by":"publisher","first-page":"NP218","DOI":"10.1093\/asj\/sjab358","article-title":"Facial aesthetic priorities and concerns: a physician and patient perception global survey","volume":"42","author":"Fabi","year":"2022","journal-title":"Aesthet Surg J"},{"key":"2025071503264257900_sjaf063-B17","doi-asserted-by":"publisher","first-page":"518e","DOI":"10.1097\/01.prs.0000475758.63709.23","article-title":"Global aesthetics consensus: botulinum toxin type A\u2013evidence-based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications","volume":"137","author":"Sundaram","year":"2016","journal-title":"Plast Reconstr Surg"},{"key":"2025071503264257900_sjaf063-B18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/DSS.0000000000001940","article-title":"Assessment of psychological well-being after abobotulinumtoxinA treatment: a comparison of 2 reconstitution volumes","volume":"46","author":"Cohen","year":"2020","journal-title":"Dermatol Surg"},{"key":"2025071503264257900_sjaf063-B19","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/DSS.0000000000002846","article-title":"A multicenter study to evaluate subject satisfaction with two treatments of abobotulinumtoxinA a year in the glabellar lines","volume":"47","author":"Schlessinger","year":"2021","journal-title":"Dermatol Surg"},{"key":"2025071503264257900_sjaf063-B20","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1111\/j.1524-4725.2010.01795.x","article-title":"A double-blind, randomized, placebo-controlled health-outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem","volume":"36","author":"Dayan","year":"2010","journal-title":"Dermatol Surg"},{"key":"2025071503264257900_sjaf063-B21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/jocd.12166","article-title":"Development and validation of a novel patient-reported treatment satisfaction measure for hyperfunctional facial lines: facial line satisfaction questionnaire","volume":"14","author":"Pompilus","year":"2015","journal-title":"J Cosmet Dermatol"},{"key":"2025071503264257900_sjaf063-B22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/PRS.0000000000000895","article-title":"FACE-Q scales for health-related quality of life, early life impact, satisfaction with outcomes, and decision to have treatment: development and validation","volume":"135","author":"Klassen","year":"2015","journal-title":"Plast Reconstr Surg"},{"key":"2025071503264257900_sjaf063-B23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamafacial.2016.0001","article-title":"Use of FACE-Q to measure quality of life following aesthetic facial treatments","volume":"18","author":"Klassen","year":"2016","journal-title":"JAMA Facial Plast Surg"},{"key":"2025071503264257900_sjaf063-B24","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jaad.2019.06.1313","article-title":"DaxibotulinumtoxinA for injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"82","author":"Bertucci","year":"2020","journal-title":"J Am Acad Dermatol"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjaf063\/62945181\/sjaf063.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/45\/8\/828\/62945181\/sjaf063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/45\/8\/828\/62945181\/sjaf063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T07:26:52Z","timestamp":1752564412000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/45\/8\/828\/8115343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4,17]]},"published-print":{"date-parts":[[2025,7,15]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjaf063","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,4,17]]}}}